Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inozyme Pharma

4.00
0.0000
Volume:- -
Turnover:- -
Market Cap:259.66M
PE:-2.38
High:4.00
Open:4.00
Low:4.00
Close:4.00
Loading ...

Company Profile

Company Name:
Inozyme Pharma
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.